Antiphospholipid Antibodies and Early Severe Preeclampsia.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01538121|
Recruitment Status : Unknown
Verified January 2015 by Osvaldo A. Reyes T., Saint Thomas Hospital, Panama.
Recruitment status was: Not yet recruiting
First Posted : February 23, 2012
Last Update Posted : January 5, 2015
|Condition or disease|
|Severe Preeclampsia Antiphospholipid Syndrome|
|Study Type :||Observational|
|Estimated Enrollment :||310 participants|
|Observational Model:||Case Control|
|Official Title:||Antiphospholipid Antibodies and Early Severe Preeclampsia (< 34 Weeks of Gestation). A Case-Control Study.|
|Study Start Date :||June 2015|
|Estimated Primary Completion Date :||July 2016|
|Estimated Study Completion Date :||August 2016|
Cases-Early Severe Preeclampsia
Patients with severe preeclampsia before 34 weeks of gestation
Patients with normal pregnancies at term.
- Lupus anticoagulant [ Time Frame: 15 months ]Number of cases positive for Lupus Anticoagulant.
- Anticardiolipin antibodies [ Time Frame: 15 months ]Number of cases with high/medium levels of IgG/IgM of anticardiolipin antibodies.
- B2 Glycoprotein I [ Time Frame: 15 months ]Number of cases with levels of B2 Glycoprotein 1 > 99%
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01538121
|Saint Thomas Maternity Hospital|
|Principal Investigator:||Osvaldo A Reyes, MD||Saint Thomas Hospital, Panama|